Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE:JNJ) reported Phase 3 MajesTEC-3 results showing TECVAYLI plus DARZALEX FASPRO significantly improved survival and response versus standard RRMM regimens at nearly three years follow-up.
Key outcomes: PFS HR 0.17 (83% risk reduction; P<0.0001), OS HR 0.46 (3-year OS 83.3% vs 65.0%), higher complete response (81.8% vs 32.1%), and higher MRD-negativity (58.4% vs 17.1%).
Safety: similar Grade 3/4 TEAE rates; higher infection rates but reduced after six months with prophylaxis.
Regulatory: sBLA submitted; U.S. FDA granted Breakthrough Therapy Designation and review via RTOR.
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast will be available on Johnson & Johnson’s Investor Relations website at www.investor.jnj.com, with an archived edition published later the same day. The audio webcast replay will be available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) reported updated CARTITUDE-4 Phase 3 results showing durable, treatment-free remissions with CARVYKTI as early as second line for relapsed or refractory multiple myeloma. In the as-treated standard-risk subgroup, the 30-month progression-free survival (PFS) rate plateaued at 80.5% (95% CI, 67.2–88.8) after a single infusion (median follow-up 33.6 months).
Of 176 patients treated in second line, 59 had standard-risk cytogenetics; all 26 patients who were MRD-negative CR at 12 months remained progression-free at 30 months. Translational analyses linked earlier-line use to stronger immune fitness (increased baseline CD4+ naïve T cells), which correlated with longer PFS.
Johnson & Johnson (NYSE:JNJ) reported Cohort 4 results from the Phase 2b SunRISe-1 study showing the gemcitabine intravesical system produced a one-year disease-free survival (DFS) of 74.3% (95% CI, 59.2-84.6) in BCG-unresponsive, high-risk, papillary-only NMIBC patients.
At median follow-up of 15.9 months, one-year progression-free survival was 95.6% and overall survival was 98%. 92.3% of patients did not undergo radical cystectomy. Treatment was generally well tolerated, with mostly low-grade urinary side effects and no treatment-related deaths.
Johnson & Johnson (NYSE: JNJ) partnered with Naomi Watts on Dec. 3, 2025 to promote eye exams as part of self-care for people over 40. A new global survey found 82% of Americans say clear vision supports confidence, yet 48% of those over 40 who think they need vision correction haven't seen an eye care professional in the past year. The release highlights presbyopia (begins ~age 40), cataracts, and that an annual eye exam can detect 270+ health conditions. The campaign urges routine comprehensive eye exams, modern corrective options, and talking to a doctor to preserve vision and independence.
Johnson & Johnson (NYSE: JNJ) reported Phase 3b APEX data showing TREMFYA (guselkumab) significantly inhibited structural joint damage in active psoriatic arthritis through Week 48 and reduced radiographic progression by 57% for placebo-switch patients from Week 24–48 (mean vdH-S 0.96 to 0.41).
TREMFYA showed ~2.5x greater inhibition versus placebo at Week 24, sustained at Week 48, and more than half of treated patients across dose groups achieved ACR50 by Week 48. Safety was consistent with the established profile and no new signals were identified. JNJ submitted an sBLA to FDA to add inhibition-of-structural-damage data to the label.
Johnson & Johnson (NYSE: JNJ) agreed to acquire Halda Therapeutics OpCo for $3.05 billion in cash, announced November 17, 2025. The deal includes Halda’s RIPTAC™ platform and lead clinical candidate HLD-0915, a once-daily therapy in a Phase 1/2 trial for prostate cancer that showed preliminary efficacy and an early safety profile. The acquisition adds earlier assets for breast, lung and other solid tumors and is expected to close within the next few months, subject to antitrust clearance and customary conditions.
Johnson & Johnson (NYSE:JNJ) announced FDA approval (Nov 6, 2025) of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as the first and only treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). The approval is based on the Phase 3 AQUILA trial, which showed DARZALEX FASPRO reduced the risk of progression to active multiple myeloma or death by 51% versus active monitoring (HR 0.49; 95% CI 0.36-0.67; P<0.001) after median 65.2 months follow-up.
Key results: 5-year non-progression 63.1% vs 40.7%; overall response rate 63.4% vs 2.0%; median time to first-line myeloma therapy not reached vs 50.2 months. Common adverse reactions ≥20% included respiratory infection, musculoskeletal pain, fatigue, diarrhea, rash, sleep disorder, sensory neuropathy, and injection site reactions.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of CAPLYTA (lumateperone) on November 6, 2025 as an adjunctive treatment with oral antidepressants for adults with major depressive disorder (MDD).
Approval was supported by two Phase 3 trials (Study 501, 502) showing MADRS separation at 6 weeks (Study 501: -4.9 points, effect size 0.61; Study 502: -4.5 points, effect size 0.56) and a 26-week open-label study where 80% responded and 65% reached remission. Safety was consistent with prior indications; no meaningful mean weight, metabolic, or sexual side‑effect increases versus placebo. CAPLYTA starts at a single 42 mg dose without titration and is now the drug's fourth FDA indication.
Johnson & Johnson (NYSE: JNJ) will present at Citi’s 2025 Global Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a Fireside Chat at 11:15 a.m. ET. A live audio webcast will be accessible via Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition will be available later the same day, and the audio webcast replay will be posted approximately 48 hours after the live session.